Pub Date : 2024-12-07DOI: 10.1016/j.ejon.2024.102758
Ruo-Lin Li, Li-Xiao Bai, Yu Liu, Ai-Ling Yang, Lu Chen, Fu-Yun Zhao, Ling Zhang, Jun-E Liu
Purpose: This study aimed to identify the potential subgroups of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing taxane-based chemotherapy and examine the association of the latent subtype with patient characteristics.
Methods: This multi-center, cross-sectional investigation was conducted between April 2022 and March 2023. CIPN was evaluated using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale. Latent class analysis was employed to identify distinct CIPN subgroups, and multinomial logistic regression was used to analyze the associations between these subgroups and patient characteristics.
Results: In total, 397 individuals were categorized into three subgroups: high symptoms with high dysfunction (Class 1; 25.4%), moderate symptoms with low dysfunction (Class 2; 39.2%), and low symptoms with low dysfunction (Class 3; 35.3%). Taxane type, chemotherapy cycles, fatigue, β-blocker use, and depression were significant predictors of the subgroups (P < .05).
Conclusion: CIPN symptoms in breast cancer patients are heterogeneous. Significant factors for the latent subgroups included taxane type, chemotherapy cycles, β-blocker use, fatigue, and depression. Identifying different subgroups of chemotherapy-induced peripheral neuropathy would help develop interventions tailored to the patients.
{"title":"Profiles of chemotherapy-induced peripheral neuropathy in breast cancer patients undergoing taxane-based chemotherapy: A latent class analysis.","authors":"Ruo-Lin Li, Li-Xiao Bai, Yu Liu, Ai-Ling Yang, Lu Chen, Fu-Yun Zhao, Ling Zhang, Jun-E Liu","doi":"10.1016/j.ejon.2024.102758","DOIUrl":"https://doi.org/10.1016/j.ejon.2024.102758","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify the potential subgroups of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing taxane-based chemotherapy and examine the association of the latent subtype with patient characteristics.</p><p><strong>Methods: </strong>This multi-center, cross-sectional investigation was conducted between April 2022 and March 2023. CIPN was evaluated using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale. Latent class analysis was employed to identify distinct CIPN subgroups, and multinomial logistic regression was used to analyze the associations between these subgroups and patient characteristics.</p><p><strong>Results: </strong>In total, 397 individuals were categorized into three subgroups: high symptoms with high dysfunction (Class 1; 25.4%), moderate symptoms with low dysfunction (Class 2; 39.2%), and low symptoms with low dysfunction (Class 3; 35.3%). Taxane type, chemotherapy cycles, fatigue, β-blocker use, and depression were significant predictors of the subgroups (P < .05).</p><p><strong>Conclusion: </strong>CIPN symptoms in breast cancer patients are heterogeneous. Significant factors for the latent subgroups included taxane type, chemotherapy cycles, β-blocker use, fatigue, and depression. Identifying different subgroups of chemotherapy-induced peripheral neuropathy would help develop interventions tailored to the patients.</p>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"102758"},"PeriodicalIF":2.7,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-07DOI: 10.1016/j.ejon.2024.102762
Grant Punnett, Melissa Perry, Charlotte Eastwood, Laura Green, Florian Walter, Janelle Yorke
Purpose: In decisions relating to cancer treatment, the risks and benefits of treatment and the patient's preferences must be considered to ensure concordance with goals of care. Shared decision making (SDM) can facilitate these discussions and is associated with reduced decision conflict. This study aimed to characterise decision making for advanced cancer patients at a UK tertiary cancer centre and identify who may be at risk of suboptimal SDM and increased decision conflict.
Methods: Participants completed the SDM-Q-9, decision conflict and decision self-efficacy scale following a consultation where an advanced cancer treatment decision was made. Pearson's chi-square test identified patient characteristics associated with SDM-Q-9, decision self-efficacy and decision conflict score categories; odds ratios were calculated to determine which patients were at increased probability of experiencing suboptimal SDM, low decision self-efficacy or high decision conflict.
Results: Participant's (n = 211) scores indicated predominantly high SDM, high decision self-efficacy and low decision conflict. Patient gender and the presence of an informal caregiver in consultation were significantly associated with SDM-Q-9 score category (p > 0.05). Female patients (OR = 2.466, 95% CI: 1.223-4.974) and those attending consultations alone (OR = 0.440, 95% CI: 0.222-0.874) had greater odds of reporting lower SDM scores.
Conclusion: High SDM scores indicate either effective SDM behaviours or satisfaction with care biasing responses. Greater support to engage with SDM is required for female patients and those who attend alone in advanced cancer treatment decision consultations.
{"title":"A cross-sectional analysis to characterise treatment decision making for advanced cancer at a tertiary treatment centre: Where can we improve the process?","authors":"Grant Punnett, Melissa Perry, Charlotte Eastwood, Laura Green, Florian Walter, Janelle Yorke","doi":"10.1016/j.ejon.2024.102762","DOIUrl":"https://doi.org/10.1016/j.ejon.2024.102762","url":null,"abstract":"<p><strong>Purpose: </strong>In decisions relating to cancer treatment, the risks and benefits of treatment and the patient's preferences must be considered to ensure concordance with goals of care. Shared decision making (SDM) can facilitate these discussions and is associated with reduced decision conflict. This study aimed to characterise decision making for advanced cancer patients at a UK tertiary cancer centre and identify who may be at risk of suboptimal SDM and increased decision conflict.</p><p><strong>Methods: </strong>Participants completed the SDM-Q-9, decision conflict and decision self-efficacy scale following a consultation where an advanced cancer treatment decision was made. Pearson's chi-square test identified patient characteristics associated with SDM-Q-9, decision self-efficacy and decision conflict score categories; odds ratios were calculated to determine which patients were at increased probability of experiencing suboptimal SDM, low decision self-efficacy or high decision conflict.</p><p><strong>Results: </strong>Participant's (n = 211) scores indicated predominantly high SDM, high decision self-efficacy and low decision conflict. Patient gender and the presence of an informal caregiver in consultation were significantly associated with SDM-Q-9 score category (p > 0.05). Female patients (OR = 2.466, 95% CI: 1.223-4.974) and those attending consultations alone (OR = 0.440, 95% CI: 0.222-0.874) had greater odds of reporting lower SDM scores.</p><p><strong>Conclusion: </strong>High SDM scores indicate either effective SDM behaviours or satisfaction with care biasing responses. Greater support to engage with SDM is required for female patients and those who attend alone in advanced cancer treatment decision consultations.</p>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"102762"},"PeriodicalIF":2.7,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-28DOI: 10.1016/j.ejon.2024.102739
Menghan Zhang, Yanyan Xue, Mengwei Shao, Yi Yang, Lulu Yu, Bin Ma, Dunhui Li, Huiyue Zhou, Kun Wang, Changying Chen, Mengzhuo Cheng, Tao Wang
Purpose: To investigate the impacts of psychoeducational interventions in adjusting the physical and psychological statuses of caregivers of CRC patients.
Methods: Nine electronic databases, including Medline, Web of Science, Embase, Cochrane Library, CINAHL Complete, CNKI, Wan Fang Database, VIP Database, and CBM, were searched to identify eligible randomized controlled trials from January 2000 to July 2023. From 1498 articles, 9 articles that met the inclusion criteria were identified and systematically analyzed. Effect sizes and moderator variables were tested using both fixed-effect models and random-effect models.
Results: Our results clearly showed that although psychoeducational interventions could improve all aspects of the physical health of caregivers of CRC patients, resulting in improved quality of life, reduced caregiver burden, and enhanced caregiver ability, they only partly affect the psychological conditions of caregivers. For example, while it led to improved positive coping, alleviated negative coping, and decreased disruption in the caring schedule, there were quite a few key aspects of the psychological status that did not show responses, including perception of family support, financial burden, self-esteem, and distress.
Conclusion: Psychoeducational interventions can significantly improve the status of caregivers of CRC both physically and psychologically and encourage active lifestyles. However, there are still outstanding problems to be solved in the psychological aspects of caregivers, such as how to improve their social support, and how to relieve their financial pressure. Even so, we firmly believe developing a standardized psychoeducational intervention mode is of great significance in improving the general well-being of caregivers of CRC patients.
Systematic review registration: PROSPERO (http://www.crd.york.ac.uk/PROSPERO), number CRD42023484775.
目的:探讨心理教育干预对调节结直肠癌患者照护者身心状态的影响。方法:检索Medline、Web of Science、Embase、Cochrane Library、CINAHL Complete、CNKI、万方数据库、VIP数据库、CBM等9个电子数据库,筛选2000年1月至2023年7月的随机对照试验。从1498篇文献中筛选出9篇符合纳入标准的文献进行系统分析。采用固定效应模型和随机效应模型对效应大小和调节变量进行检验。结果:我们的研究结果清楚地表明,虽然心理教育干预可以改善CRC患者照顾者各方面的身体健康,从而改善生活质量,减轻照顾者负担,增强照顾者能力,但仅部分影响照顾者的心理状况。例如,虽然它改善了积极应对,减轻了消极应对,减少了照顾计划的中断,但心理状态的许多关键方面没有表现出反应,包括对家庭支持的感知,经济负担,自尊和痛苦。结论:心理教育干预能显著改善结直肠癌照护者的生理和心理状况,鼓励积极的生活方式。然而,在照顾者的心理方面仍有突出的问题需要解决,如如何提高他们的社会支持,如何缓解他们的经济压力。尽管如此,我们坚信,制定标准化的心理教育干预模式对于提高CRC患者照护者的整体幸福感具有重要意义。系统评价注册:PROSPERO (http://www.crd.york.ac.uk/PROSPERO),编号CRD42023484775。
{"title":"The effects of a psychoeducational intervention on caregivers of colorectal cancer patients: A meta-analysis of randomized controlled trials.","authors":"Menghan Zhang, Yanyan Xue, Mengwei Shao, Yi Yang, Lulu Yu, Bin Ma, Dunhui Li, Huiyue Zhou, Kun Wang, Changying Chen, Mengzhuo Cheng, Tao Wang","doi":"10.1016/j.ejon.2024.102739","DOIUrl":"https://doi.org/10.1016/j.ejon.2024.102739","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the impacts of psychoeducational interventions in adjusting the physical and psychological statuses of caregivers of CRC patients.</p><p><strong>Methods: </strong>Nine electronic databases, including Medline, Web of Science, Embase, Cochrane Library, CINAHL Complete, CNKI, Wan Fang Database, VIP Database, and CBM, were searched to identify eligible randomized controlled trials from January 2000 to July 2023. From 1498 articles, 9 articles that met the inclusion criteria were identified and systematically analyzed. Effect sizes and moderator variables were tested using both fixed-effect models and random-effect models.</p><p><strong>Results: </strong>Our results clearly showed that although psychoeducational interventions could improve all aspects of the physical health of caregivers of CRC patients, resulting in improved quality of life, reduced caregiver burden, and enhanced caregiver ability, they only partly affect the psychological conditions of caregivers. For example, while it led to improved positive coping, alleviated negative coping, and decreased disruption in the caring schedule, there were quite a few key aspects of the psychological status that did not show responses, including perception of family support, financial burden, self-esteem, and distress.</p><p><strong>Conclusion: </strong>Psychoeducational interventions can significantly improve the status of caregivers of CRC both physically and psychologically and encourage active lifestyles. However, there are still outstanding problems to be solved in the psychological aspects of caregivers, such as how to improve their social support, and how to relieve their financial pressure. Even so, we firmly believe developing a standardized psychoeducational intervention mode is of great significance in improving the general well-being of caregivers of CRC patients.</p><p><strong>Systematic review registration: </strong>PROSPERO (http://www.crd.york.ac.uk/PROSPERO), number CRD42023484775.</p>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"102739"},"PeriodicalIF":2.7,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-27DOI: 10.1016/j.ejon.2024.102749
Ivo C S Paiva, Filipa I Q S Ventura, António C L Vilela, Isabel M P B Moreira
Purpose: To identify Missed Nursing Care (MNC) and related factors, as well as analyze the influence of nurses' decision-making and personality traits on MNC in two Portuguese hospitals dedicated to cancer care.
Methods: A cross-sectional, multicentric, descriptive-correlational study was conducted using a convenience sample of 298 nurses working in two hospitals dedicated to cancer care. Data were collected in the first semester of 2023 using a questionnaire that included sociodemographic and professional questions and the Portuguese versions of the MISSCARE Survey, the Nursing Decision-Making Instrument (NDMI-PT), and the Ten-Item Personality Inventory (TIPI-P).
Results: Nurses missed care occasionally, namely in the dimensions related to Patient empowerment/autonomy care and Efficacy of feeding and medication. Staffing, Patient volume and acuity, and Management and organization were moderate to significant reasons for MNC. The flexible decision-making style was predominant (81.5%). The most prevalent personality traits were Conscientiousness, Agreeableness, and Openness to experience. Significant correlations were found between the four stages of the decision-making process and the personality traits and several dimensions of MNC. Data collection to assess a patient's condition was negatively correlated with Team communication and Material resources. Similarly, the Emotional stability trait was negatively correlated with Team communication and Patient volume and acuity.
Conclusions: This study identified MNC and factors that can influence the quality of care. It is crucial to promote nurses' training and specialization within healthcare teams, with a particular focus on enhancing some of their personality traits to make them more effective and efficient therapeutic agents.
{"title":"Influence of oncology nurses' decision-making and personality traits on missed nursing care and related factors: A correlational study.","authors":"Ivo C S Paiva, Filipa I Q S Ventura, António C L Vilela, Isabel M P B Moreira","doi":"10.1016/j.ejon.2024.102749","DOIUrl":"https://doi.org/10.1016/j.ejon.2024.102749","url":null,"abstract":"<p><strong>Purpose: </strong>To identify Missed Nursing Care (MNC) and related factors, as well as analyze the influence of nurses' decision-making and personality traits on MNC in two Portuguese hospitals dedicated to cancer care.</p><p><strong>Methods: </strong>A cross-sectional, multicentric, descriptive-correlational study was conducted using a convenience sample of 298 nurses working in two hospitals dedicated to cancer care. Data were collected in the first semester of 2023 using a questionnaire that included sociodemographic and professional questions and the Portuguese versions of the MISSCARE Survey, the Nursing Decision-Making Instrument (NDMI-PT), and the Ten-Item Personality Inventory (TIPI-P).</p><p><strong>Results: </strong>Nurses missed care occasionally, namely in the dimensions related to Patient empowerment/autonomy care and Efficacy of feeding and medication. Staffing, Patient volume and acuity, and Management and organization were moderate to significant reasons for MNC. The flexible decision-making style was predominant (81.5%). The most prevalent personality traits were Conscientiousness, Agreeableness, and Openness to experience. Significant correlations were found between the four stages of the decision-making process and the personality traits and several dimensions of MNC. Data collection to assess a patient's condition was negatively correlated with Team communication and Material resources. Similarly, the Emotional stability trait was negatively correlated with Team communication and Patient volume and acuity.</p><p><strong>Conclusions: </strong>This study identified MNC and factors that can influence the quality of care. It is crucial to promote nurses' training and specialization within healthcare teams, with a particular focus on enhancing some of their personality traits to make them more effective and efficient therapeutic agents.</p>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"102749"},"PeriodicalIF":2.7,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-22DOI: 10.1016/j.ejon.2024.102748
Louise Elkjær Fløe, Josefine Maria Bruun, Jesper Grau Eriksen, Poul Videbech, Mette Asbjørn Neergaard, Anna Mygind
Purpose: Cancer patients with pre-existing severe mental disorders (SMD), including moderate to severe depression, bipolar disorder and schizophrenia, have reduced life expectancy and are less likely to receive optimal cancer treatment. The aim of this study is to develop and pilot test a supportive care model, to enhance cancer care in this population.
Methods: The model was developed through three phases. In phase I, a barrier analysis and prototype of the model were conducted from reviewing the literature and through 162 informal interviews with healthcare professionals, patients and patient representatives. In phase II, the prototype was refined through four workshops with a total of five cancer nurses, four clinical oncologists, three psychiatrists, two general practitioners, one psychologist, and 16 patient representatives. Thereafter, a pilot test with 13 patients was carried out, where continuous adaptations to the prototype from phase II, were made. The quantitative and qualitative data were analysed focusing on components which were prominent and able to fit into the clinical setting.
Results: The final CASEMED supportive cancer care model included: Early identification of psychiatric comorbidity, engagement of significant caregivers, education of the oncological HCPs, securing continuity among staff and enhanced collaboration between sectors. The latter was achieved through an online psychiatric multidisciplinary team conference where the patient's general practitioner, a psychiatrist and the patient's oncologist participated.
Conclusion: This study indicates that the model can be implemented in practice and has the potential to optimize cancer care for patients with cancer and pre-existing SMD. A larger feasibility study is currently being conducted.
{"title":"Development of a supportive cancer care model for patients with CAncer and pre-existing SEvere MEntal Disorders.","authors":"Louise Elkjær Fløe, Josefine Maria Bruun, Jesper Grau Eriksen, Poul Videbech, Mette Asbjørn Neergaard, Anna Mygind","doi":"10.1016/j.ejon.2024.102748","DOIUrl":"https://doi.org/10.1016/j.ejon.2024.102748","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer patients with pre-existing severe mental disorders (SMD), including moderate to severe depression, bipolar disorder and schizophrenia, have reduced life expectancy and are less likely to receive optimal cancer treatment. The aim of this study is to develop and pilot test a supportive care model, to enhance cancer care in this population.</p><p><strong>Methods: </strong>The model was developed through three phases. In phase I, a barrier analysis and prototype of the model were conducted from reviewing the literature and through 162 informal interviews with healthcare professionals, patients and patient representatives. In phase II, the prototype was refined through four workshops with a total of five cancer nurses, four clinical oncologists, three psychiatrists, two general practitioners, one psychologist, and 16 patient representatives. Thereafter, a pilot test with 13 patients was carried out, where continuous adaptations to the prototype from phase II, were made. The quantitative and qualitative data were analysed focusing on components which were prominent and able to fit into the clinical setting.</p><p><strong>Results: </strong>The final CASEMED supportive cancer care model included: Early identification of psychiatric comorbidity, engagement of significant caregivers, education of the oncological HCPs, securing continuity among staff and enhanced collaboration between sectors. The latter was achieved through an online psychiatric multidisciplinary team conference where the patient's general practitioner, a psychiatrist and the patient's oncologist participated.</p><p><strong>Conclusion: </strong>This study indicates that the model can be implemented in practice and has the potential to optimize cancer care for patients with cancer and pre-existing SMD. A larger feasibility study is currently being conducted.</p>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"102748"},"PeriodicalIF":2.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-19DOI: 10.1016/j.ejon.2024.102740
Lynn Leppla , Klaus Kaier , Anja Schmid , Sabine Valenta , Janette Ribaut , Juliane Mielke , Alexandra Teynor , Robert Zeiser , Sabina De Geest , SMILe study team
<div><h3>Purpose</h3><div>eHealth-facilitated integrated care models (eICMs) have proved effective in improving outcomes for chronically ill patients. However, evidence on cost-effectiveness of eICMs is scarce so far. Allogeneic stem cell transplantation (alloSCT) recipients' post-discharge treatment costs and mortality are greatly influenced by complications. Within the international, multicentric SMILe implementation science project, the eHealth-facilitated SMILe integrated care model (SMILe–<span>ICM</span>) was developed to support patients minimize complications' effects within the first year post-alloSCT.</div><div>Using initial effectiveness findings from the first center that implemented the SMILe-ICM, this study provides a cost and cost-effectiveness evaluation considering one-year and long-term survival effects, post-discharge costs, and patient-related factors.</div></div><div><h3>Methods</h3><div>A single-center hybrid effectiveness implementation randomized controlled trial was conducted at a German university hospital from 2/2020 to 8/2022. Eligible alloSCT patients were randomized to the SMILe–ICM or usual care, i.e., one pre-transplant educational nursing visit followed by a physician-led follow-up. The intervention group received usual care plus the SMILe-ICM's four intervention modules (i.e., monitoring of medical/symptom-related parameters, medication adherence, infection prevention, physical activity). All modules were delivered by Advanced Practice Nurses (APNs) in face-to-face visits, combined with continuous online support. Daily, patients entered seventeen medical and symptom-related parameters to the SMILe App, so that APNs could monitor for and investigate possible pre-complication signs. Healthcare utilization costs were assessed at eight time-points (d+30 post-alloSCT–d365) on fourteen self-reported cost indicators and validated against health records. To calculate costs, we applied German standardized unit costs. Cost- and cost-effectiveness were analyzed in five steps: 1.) Calculate total costs, including for the alloSCT inpatient stay and post-discharge follow-up. 2.) Determine life-years gained (survival) as a health benefit unit. 3.) Calculate overall and rehospitalization-free survival estimates. 4.) Calculate the intervention's long-term cost-effectiveness, including extended follow-up, rate of survival until day 1000, and restricted mean survival time. 5.) Contrast these long-term estimates to current post-discharge costs with comparable patient-related factors (age ≥ or < 65, living alone, gender).</div></div><div><h3>Results</h3><div>Seventy-two patients participated (n = 36/group). Total intergroup healthcare utilization and post-discharge costs differed, but non-significantly. Survival rates improved with the SMILe–ICM (88% vs. 80%) at least until day +1000. Rehospitalization-free survival showed improvement (38% vs. 30%); however, considering this sample size, both findings were nonsignificant. Cost-eff
{"title":"Evaluating the cost, cost-effectiveness and survival of an eHealth-facilitated integrated care model for allogeneic stem cell transplantation: Results of the German SMILe randomized, controlled implementation science trial","authors":"Lynn Leppla , Klaus Kaier , Anja Schmid , Sabine Valenta , Janette Ribaut , Juliane Mielke , Alexandra Teynor , Robert Zeiser , Sabina De Geest , SMILe study team","doi":"10.1016/j.ejon.2024.102740","DOIUrl":"10.1016/j.ejon.2024.102740","url":null,"abstract":"<div><h3>Purpose</h3><div>eHealth-facilitated integrated care models (eICMs) have proved effective in improving outcomes for chronically ill patients. However, evidence on cost-effectiveness of eICMs is scarce so far. Allogeneic stem cell transplantation (alloSCT) recipients' post-discharge treatment costs and mortality are greatly influenced by complications. Within the international, multicentric SMILe implementation science project, the eHealth-facilitated SMILe integrated care model (SMILe–<span>ICM</span>) was developed to support patients minimize complications' effects within the first year post-alloSCT.</div><div>Using initial effectiveness findings from the first center that implemented the SMILe-ICM, this study provides a cost and cost-effectiveness evaluation considering one-year and long-term survival effects, post-discharge costs, and patient-related factors.</div></div><div><h3>Methods</h3><div>A single-center hybrid effectiveness implementation randomized controlled trial was conducted at a German university hospital from 2/2020 to 8/2022. Eligible alloSCT patients were randomized to the SMILe–ICM or usual care, i.e., one pre-transplant educational nursing visit followed by a physician-led follow-up. The intervention group received usual care plus the SMILe-ICM's four intervention modules (i.e., monitoring of medical/symptom-related parameters, medication adherence, infection prevention, physical activity). All modules were delivered by Advanced Practice Nurses (APNs) in face-to-face visits, combined with continuous online support. Daily, patients entered seventeen medical and symptom-related parameters to the SMILe App, so that APNs could monitor for and investigate possible pre-complication signs. Healthcare utilization costs were assessed at eight time-points (d+30 post-alloSCT–d365) on fourteen self-reported cost indicators and validated against health records. To calculate costs, we applied German standardized unit costs. Cost- and cost-effectiveness were analyzed in five steps: 1.) Calculate total costs, including for the alloSCT inpatient stay and post-discharge follow-up. 2.) Determine life-years gained (survival) as a health benefit unit. 3.) Calculate overall and rehospitalization-free survival estimates. 4.) Calculate the intervention's long-term cost-effectiveness, including extended follow-up, rate of survival until day 1000, and restricted mean survival time. 5.) Contrast these long-term estimates to current post-discharge costs with comparable patient-related factors (age ≥ or < 65, living alone, gender).</div></div><div><h3>Results</h3><div>Seventy-two patients participated (n = 36/group). Total intergroup healthcare utilization and post-discharge costs differed, but non-significantly. Survival rates improved with the SMILe–ICM (88% vs. 80%) at least until day +1000. Rehospitalization-free survival showed improvement (38% vs. 30%); however, considering this sample size, both findings were nonsignificant. Cost-eff","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"Article 102740"},"PeriodicalIF":2.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142697411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-16DOI: 10.1016/j.ejon.2024.102737
Jiali Gong, Meizhen Chen, Huamin Luo, Qiuping Li
Purpose: This study aimed to assess the feasibility and acceptability of a couple-based self-efficacy (SE) intervention, and to examine the effects of the intervention on health outcomes for CRC couples.
Methods: An assessor-blinded, two-armed, randomized controlled design was used. The study randomly assigned 144 patients hospitalized for colorectal cancer to receive either the SE intervention or the usual care. SE was the primary outcome. The secondary outcomes included quality of life and mental health (positive emotions and negative emotions). Repeated measures analysis of variance was used to examine the data.
Results: The recruitment and retention rates were 80% and 87.5%, respectively. First, we found that patients scored significantly higher on anxiety (p = 0.001), depression (p = 0.001) and benefit findings (p = 0.009) than did spousal caregivers, whereas spousal caregivers scored significantly higher than patients on the quality of life (p < 0.001 for both physical scores and mental scores) in the SE group. Second, immediately after the intervention, the SE group showed statistically significant improvements were found in SE (p < 0.001 for both couples), quality of life (mental scores) (p = 0.002 for spousal caregivers), negative emotion (anxiety, p < 0.05 for both couples; depression, p = 0.03 for patients), and positive emotion (benefit findings) (p < 0.001 for both couple) when compared to the control group.
Conclusion: A couple-based SE intervention significantly improved SE, quality of life (mental scores), and psychological well-being, suggesting a short-term intervention effect.
{"title":"Effects of a couple-based self-efficacy intervention on health outcomes among colorectal cancer patients and spousal caregivers: A randomized controlled trial.","authors":"Jiali Gong, Meizhen Chen, Huamin Luo, Qiuping Li","doi":"10.1016/j.ejon.2024.102737","DOIUrl":"https://doi.org/10.1016/j.ejon.2024.102737","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the feasibility and acceptability of a couple-based self-efficacy (SE) intervention, and to examine the effects of the intervention on health outcomes for CRC couples.</p><p><strong>Methods: </strong>An assessor-blinded, two-armed, randomized controlled design was used. The study randomly assigned 144 patients hospitalized for colorectal cancer to receive either the SE intervention or the usual care. SE was the primary outcome. The secondary outcomes included quality of life and mental health (positive emotions and negative emotions). Repeated measures analysis of variance was used to examine the data.</p><p><strong>Results: </strong>The recruitment and retention rates were 80% and 87.5%, respectively. First, we found that patients scored significantly higher on anxiety (p = 0.001), depression (p = 0.001) and benefit findings (p = 0.009) than did spousal caregivers, whereas spousal caregivers scored significantly higher than patients on the quality of life (p < 0.001 for both physical scores and mental scores) in the SE group. Second, immediately after the intervention, the SE group showed statistically significant improvements were found in SE (p < 0.001 for both couples), quality of life (mental scores) (p = 0.002 for spousal caregivers), negative emotion (anxiety, p < 0.05 for both couples; depression, p = 0.03 for patients), and positive emotion (benefit findings) (p < 0.001 for both couple) when compared to the control group.</p><p><strong>Conclusion: </strong>A couple-based SE intervention significantly improved SE, quality of life (mental scores), and psychological well-being, suggesting a short-term intervention effect.</p>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"102737"},"PeriodicalIF":2.7,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
the aim of the study is to evaluate the presence of fatigue syndrome, the quality of life and functional ability of patients with bone and soft tissue sarcomas during the first 6 months of chemotherapy and identify possible prognostic factors.
Methods
prospective observational study was conducted. All patients about to start chemotherapy were consecutively recruited from July 2019 to April 2021. Patient fatigue, quality of life was measured at the start of chemotherapy and after 6 months. BFI score and EORTC QLQ C-30 was used respectively.
Results
The analysis of risk factors was performed on 98 patients. According to BFI score, in 36% of patients fatigue was classified from moderate to severe. The average global quality of life and TESS score increased by 3.9 and 8.5 points respectively. The strength of the association between the BFI score and EORTC subscales and TESS score was moderate (p < 0.001). Smoking status, higher BMI and impaired functional capabilities were independent predictive factors of fatigue.
Conclusion
Fatigue syndrome is present in a significant percentage of patients both at the start of chemotherapy treatment and in the following 6 months. Being a no smoker, higher BMI and impaired functional ability could impact fatigue syndrome. Fatigue screening, patient education and adapted aerobic exercise should be encouraged from the beginning of chemotherapy treatment. The quality of life and functional ability are associated with fatigue syndrome.
{"title":"Fatigue, functional ability and quality of life in patients with bone and soft tissue sarcomas undergoing chemotherapy treatment: An observational study","authors":"Mattia Morri, Riccardo Boccomino, Eugenio Brruku, Erika Romagnoli, Rita Boschi, Giovanni Raucci, Ausilia Bellina Terra, Paola Coluccino","doi":"10.1016/j.ejon.2024.102736","DOIUrl":"10.1016/j.ejon.2024.102736","url":null,"abstract":"<div><h3>Purpose</h3><div>the aim of the study is to evaluate the presence of fatigue syndrome, the quality of life and functional ability of patients with bone and soft tissue sarcomas during the first 6 months of chemotherapy and identify possible prognostic factors.</div></div><div><h3>Methods</h3><div>prospective observational study was conducted. All patients about to start chemotherapy were consecutively recruited from July 2019 to April 2021. Patient fatigue, quality of life was measured at the start of chemotherapy and after 6 months. BFI score and EORTC QLQ C-30 was used respectively.</div></div><div><h3>Results</h3><div>The analysis of risk factors was performed on 98 patients. According to BFI score, in 36% of patients fatigue was classified from moderate to severe. The average global quality of life and TESS score increased by 3.9 and 8.5 points respectively. The strength of the association between the BFI score and EORTC subscales and TESS score was moderate (p < 0.001). Smoking status, higher BMI and impaired functional capabilities were independent predictive factors of fatigue.</div></div><div><h3>Conclusion</h3><div>Fatigue syndrome is present in a significant percentage of patients both at the start of chemotherapy treatment and in the following 6 months. Being a no smoker, higher BMI and impaired functional ability could impact fatigue syndrome. Fatigue screening, patient education and adapted aerobic exercise should be encouraged from the beginning of chemotherapy treatment. The quality of life and functional ability are associated with fatigue syndrome.</div></div><div><h3>Registration number (clinicaltrial.gov)</h3><div>NCT04104750 (26/09/2019)</div></div>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"Article 102736"},"PeriodicalIF":2.7,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-16DOI: 10.1016/j.ejon.2024.102735
Baoyi Zhang , Ni Zhang , Ye Zhang , Jingwen Yan , Lili Chen , Haiyan He , Shihao Sun , Yiheng Zhang , Meifen Zhang
Purpose
Chemotherapy-induced taste alterations (CiTA) are significant predictors of gastrointestinal symptoms, malnutrition, and poor prognosis. However, the prevalence and risk factors of CiTA vary substantially between studies. This study aimed to synthesize the prevalence and risk factors of CiTA among cancer patients.
Methods
Eight databases (Pubmed, Web of Science, Embase, ScienceDirect, Sinomed, China National Knowledge Infrastructure, Wanfang and Weipu database) were retrieved to collect observational studies regarding the prevalence or risk factors of CiTA published before June 1, 2024. The random effects meta-analysis was conducted to estimate the pooled prevalence. Subgroup analysis was conducted to identify heterogeneity across studies. For the same risk factor, the odds ratio and 95% confidence interval were calculated.
Results
In total, 30 studies with 15,722 participants were included. The pooled prevalence of CiTA was 70.0% (95% CI: 59.1%–79.9%, I2 = 99.4%), ranging from 21.0% to 100.0%. Female (OR = 2.59, 95% CI: 1.59 to 4.22), patients with xerostomia (OR = 2.04, 95% CI: 1.48 to 2.81), oral mucositis/ulcers (OR = 3.72, 95% CI: 1.46 to 9.47), receiving not less than 2 chemotherapy cycles (OR = 3.95, 95% CI: 3.20 to 4.88) were more likely to develop CiTA.
Conclusions
The prevalence of CiTA among cancer patients was alarmingly high. Female, xerostomia, oral mucositis/ulcers, receiving not less than 2 chemotherapy cycles were significant risk factors of CiTA. Healthcare practitioners should identify high-risk patients and develop targeted interventions to manage CiTA based on identified risk factors.
目的:化疗引起的味觉改变(CiTA)是预测胃肠道症状、营养不良和预后不良的重要因素。然而,不同研究对 CiTA 的发生率和风险因素的研究差异很大。本研究旨在综合癌症患者中 CiTA 的患病率和风险因素:检索8个数据库(Pubmed、Web of Science、Embase、ScienceDirect、Sinomed、中国国家知识基础设施、万方和卫普数据库),收集2024年6月1日前发表的有关CiTA患病率或危险因素的观察性研究。采用随机效应荟萃分析法估算汇总患病率。为确定不同研究间的异质性,还进行了分组分析。对于同一风险因素,计算了几率比和 95% 的置信区间:共纳入了 30 项研究,15722 名参与者。汇总的 CiTA 患病率为 70.0%(95% CI:59.1%-79.9%,I2 = 99.4%),范围从 21.0% 到 100.0%。女性(OR = 2.59,95% CI:1.59 至 4.22)、有口腔干燥症(OR = 2.04,95% CI:1.48 至 2.81)、口腔粘膜炎/溃疡(OR = 3.72,95% CI:1.46 至 9.47)、接受不少于 2 个化疗周期(OR = 3.95,95% CI:3.20 至 4.88)的患者更有可能患上 CiTA:结论:CiTA在癌症患者中的发病率之高令人震惊。女性、口腔干燥症、口腔粘膜炎/溃疡、接受不少于 2 个化疗周期是 CiTA 的重要风险因素。医护人员应识别高危患者,并根据识别出的风险因素制定有针对性的干预措施来控制 CiTA。
{"title":"Prevalence and risk factors of chemotherapy-induced taste alterations among cancer patients: A systematic review and meta-analysis","authors":"Baoyi Zhang , Ni Zhang , Ye Zhang , Jingwen Yan , Lili Chen , Haiyan He , Shihao Sun , Yiheng Zhang , Meifen Zhang","doi":"10.1016/j.ejon.2024.102735","DOIUrl":"10.1016/j.ejon.2024.102735","url":null,"abstract":"<div><h3>Purpose</h3><div>Chemotherapy-induced taste alterations (CiTA) are significant predictors of gastrointestinal symptoms, malnutrition, and poor prognosis. However, the prevalence and risk factors of CiTA vary substantially between studies. This study aimed to synthesize the prevalence and risk factors of CiTA among cancer patients.</div></div><div><h3>Methods</h3><div>Eight databases (Pubmed, Web of Science, Embase, ScienceDirect, Sinomed, China National Knowledge Infrastructure, Wanfang and Weipu database) were retrieved to collect observational studies regarding the prevalence or risk factors of CiTA published before June 1, 2024. The random effects meta-analysis was conducted to estimate the pooled prevalence. Subgroup analysis was conducted to identify heterogeneity across studies. For the same risk factor, the odds ratio and 95% confidence interval were calculated.</div></div><div><h3>Results</h3><div>In total, 30 studies with 15,722 participants were included. The pooled prevalence of CiTA was 70.0% (95% <em>CI</em>: 59.1%–79.9%, <em>I</em><sup><em>2</em></sup> = 99.4%), ranging from 21.0% to 100.0%. Female (<em>OR</em> = 2.59, 95% <em>CI</em>: 1.59 to 4.22), patients with xerostomia (<em>OR</em> = 2.04, 95% <em>CI</em>: 1.48 to 2.81), oral mucositis/ulcers (<em>OR</em> = 3.72, 95% <em>CI</em>: 1.46 to 9.47), receiving not less than 2 chemotherapy cycles (<em>OR</em> = 3.95, 95% <em>CI</em>: 3.20 to 4.88) were more likely to develop CiTA.</div></div><div><h3>Conclusions</h3><div>The prevalence of CiTA among cancer patients was alarmingly high. Female, xerostomia, oral mucositis/ulcers, receiving not less than 2 chemotherapy cycles were significant risk factors of CiTA. Healthcare practitioners should identify high-risk patients and develop targeted interventions to manage CiTA based on identified risk factors.</div></div>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"Article 102735"},"PeriodicalIF":2.7,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-15DOI: 10.1016/j.ejon.2024.102734
Shuhan Li , Qingxin Mai , Xiaoxiao Mei , Yingting Jiang , Ying Xiong , Yihao Zeng , M.Tish Knobf , Zengjie Ye
Purpose
To estimate the longitudinal association between resilience and sleep quality in patients with newly diagnosed breast cancer within the first 6 months.
Method
Between July 2023 and September 2023, 155 newly diagnosed BC patients were recruited to participate in the Be Resilience to Breast Cancer program (Abbreviated as BRBC). They completed the 10-item Connor-Davidson Resilience scale and Pittsburgh Sleep Quality Index Scale. The following three timepoints were set to collect the data, including 1 month after initial diagnosis (T0), 3 months (T1), and 6 months (T2). Data were analyzed using Cross-lagged Panel Model (CLPM), and Parallel Latent Growth Model (PLGM).
Results
Excluded questionnaires with a large number of missing items and finally 125 patients were included, with the response rate of 83.3%. CLPM indicated that resilience at T1 predicted PSQI at T2 (r = −0.168, P 0.001), and PSQI at T1 predicted resilience at T2 (r = −0.112, P 0.001). PLGM demonstrated that changes in resilience was significantly associated with changes in PSQI (r = −0.874, P 0.001).
Conclusion
A longitudinal association between resilience and sleep quality was confirmed in patients with newly diagnosed breast cancer. Resilience was a protective factor in the development of sleep quality.
{"title":"The longitudinal association between resilience and sleep quality in breast cancer","authors":"Shuhan Li , Qingxin Mai , Xiaoxiao Mei , Yingting Jiang , Ying Xiong , Yihao Zeng , M.Tish Knobf , Zengjie Ye","doi":"10.1016/j.ejon.2024.102734","DOIUrl":"10.1016/j.ejon.2024.102734","url":null,"abstract":"<div><h3>Purpose</h3><div>To estimate the longitudinal association between resilience and sleep quality in patients with newly diagnosed breast cancer within the first 6 months.</div></div><div><h3>Method</h3><div>Between July 2023 and September 2023, 155 newly diagnosed BC patients were recruited to participate in the Be Resilience to Breast Cancer program (Abbreviated as BRBC). They completed the 10-item Connor-Davidson Resilience scale and Pittsburgh Sleep Quality Index Scale. The following three timepoints were set to collect the data, including 1 month after initial diagnosis (T0), 3 months (T1), and 6 months (T2). Data were analyzed using Cross-lagged Panel Model (CLPM), and Parallel Latent Growth Model (PLGM).</div></div><div><h3>Results</h3><div>Excluded questionnaires with a large number of missing items and finally 125 patients were included, with the response rate of 83.3%. CLPM indicated that resilience at T1 predicted PSQI at T2 (r = −0.168, P <span><math><mrow><mo><</mo></mrow></math></span> 0.001), and PSQI at T1 predicted resilience at T2 (r = −0.112, P<span><math><mrow><mo><</mo></mrow></math></span> 0.001). PLGM demonstrated that changes in resilience was significantly associated with changes in PSQI (r = −0.874, P<span><math><mrow><mo><</mo></mrow></math></span> 0.001).</div></div><div><h3>Conclusion</h3><div>A longitudinal association between resilience and sleep quality was confirmed in patients with newly diagnosed breast cancer. Resilience was a protective factor in the development of sleep quality.</div></div>","PeriodicalId":51048,"journal":{"name":"European Journal of Oncology Nursing","volume":"74 ","pages":"Article 102734"},"PeriodicalIF":2.7,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}